Yifeng Pharmacy Chain Co., Ltd.

XSSC:603939 Stock Report

Market Cap: CN¥27.8b

Yifeng Pharmacy Chain Valuation

Is 603939 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603939 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CN¥188.17
Fair Value
87.8% undervalued intrinsic discount
13
Number of Analysts

Below Fair Value: 603939 (CN¥22.9) is trading below our estimate of fair value (CN¥188.17)

Significantly Below Fair Value: 603939 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603939?

Key metric: As 603939 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603939. This is calculated by dividing 603939's market cap by their current earnings.
What is 603939's PE Ratio?
PE Ratio18.2x
EarningsCN¥1.52b
Market CapCN¥27.76b

Price to Earnings Ratio vs Peers

How does 603939's PE Ratio compare to its peers?

The above table shows the PE ratio for 603939 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28x
603233 DaShenLin Pharmaceutical Group
19x21.2%CN¥16.1b
603883 LBX Pharmacy Chain
14.3x15.5%CN¥12.0b
002727 Yixintang Pharmaceutical Group
46.8x38.5%CN¥7.3b
301408 Anhui Huaren Health Pharmaceutical
32.2xn/aCN¥4.3b
603939 Yifeng Pharmacy Chain
18.2x16.4%CN¥27.8b

Price-To-Earnings vs Peers: 603939 is good value based on its Price-To-Earnings Ratio (18.2x) compared to the peer average (28x).

Price to Earnings Ratio vs Industry

How does 603939's PE Ratio compare vs other companies in the CN Consumer Retailing Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
No. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603939 is good value based on its Price-To-Earnings Ratio (18.2x) compared to the CN Consumer Retailing industry average (25.4x).

Price to Earnings Ratio vs Fair Ratio

What is 603939's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603939 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.2x
Fair PE Ratio24.9x

Price-To-Earnings vs Fair Ratio: 603939 is good value based on its Price-To-Earnings Ratio (18.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603939 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥22.90
CN¥36.30
+58.5%
25.2%CN¥58.00CN¥20.80n/a13
Jan ’26CN¥24.13
CN¥36.30
+50.4%
25.2%CN¥58.00CN¥20.80n/a13
Dec ’25CN¥23.42
CN¥36.57
+56.2%
20.5%CN¥48.33CN¥20.80n/a15
Nov ’25CN¥26.10
CN¥36.31
+39.1%
20.8%CN¥48.33CN¥25.00n/a15
Oct ’25CN¥25.52
CN¥37.27
+46.0%
20.1%CN¥48.33CN¥25.00n/a14
Sep ’25CN¥20.17
CN¥41.66
+106.5%
11.0%CN¥48.33CN¥29.90n/a13
Aug ’25CN¥20.14
CN¥42.98
+113.4%
7.7%CN¥48.33CN¥37.30n/a13
Jul ’25CN¥25.61
CN¥44.33
+73.1%
8.0%CN¥48.33CN¥37.30n/a13
Jun ’25CN¥37.55
CN¥44.70
+19.0%
6.4%CN¥48.33CN¥39.63n/a13
May ’25CN¥36.62
CN¥43.38
+18.5%
7.3%CN¥47.17CN¥36.50n/a10
Apr ’25CN¥33.30
CN¥43.02
+29.2%
7.8%CN¥48.33CN¥36.50n/a12
Mar ’25CN¥32.96
CN¥42.74
+29.7%
8.1%CN¥48.33CN¥36.50n/a11
Feb ’25CN¥32.18
CN¥42.74
+32.8%
8.1%CN¥48.33CN¥36.50CN¥22.9011
Jan ’25CN¥33.37
CN¥39.80
+19.3%
15.0%CN¥48.33CN¥27.98CN¥24.1311
Dec ’24CN¥31.96
CN¥39.73
+24.3%
14.8%CN¥48.33CN¥27.98CN¥23.4211
Nov ’24CN¥28.61
CN¥39.84
+39.3%
14.2%CN¥48.33CN¥27.98CN¥26.1012
Oct ’24CN¥29.23
CN¥40.57
+38.8%
14.4%CN¥48.33CN¥27.98CN¥25.5212
Sep ’24CN¥29.17
CN¥39.58
+35.7%
13.4%CN¥48.33CN¥27.98CN¥20.1712
Aug ’24CN¥32.10
CN¥37.68
+17.4%
14.3%CN¥48.33CN¥27.98CN¥20.1411
Jul ’24CN¥30.83
CN¥38.42
+24.6%
13.0%CN¥45.83CN¥27.98CN¥25.6111
Jun ’24CN¥29.66
CN¥39.83
+34.3%
12.2%CN¥45.83CN¥27.98CN¥37.5510
May ’24CN¥29.65
CN¥40.13
+35.3%
14.9%CN¥45.83CN¥26.79CN¥36.628
Apr ’24CN¥34.42
CN¥39.90
+15.9%
16.6%CN¥49.40CN¥26.79CN¥33.308
Mar ’24CN¥35.31
CN¥40.27
+14.0%
17.2%CN¥49.40CN¥26.79CN¥32.968
Feb ’24CN¥34.58
CN¥39.90
+15.4%
16.6%CN¥49.40CN¥26.79CN¥32.188
Analyst Price Target
Consensus Narrative from 13 Analysts
CN¥36.30
Fair Value
36.9% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 09:26
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yifeng Pharmacy Chain Co., Ltd. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethan CuiBofA Global Research
Hao WuChasing Securities
Qianyi LiChina International Capital Corporation Limited